Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity.
OBJECTIVE
To evaluate macular thickness profiles using spectral-domain optical coherence tomography (SDOCT) and image segmentation in patients with chronic exposure to hydroxychloroquine.


METHODS
This study included eight patients with chronic exposure to hydroxychloroquine (group 1) and eight controls (group 2). Group 1 patients had no clinically evident retinal toxicity. All subjects underwent SDOCT imaging of the macula. An image segmentation technique was used to measure thickness of six retinal layers at 200 microm intervals. A mixed-effects model was used for multivariate analysis.


RESULTS
By measuring total retinal thickness either at the central macular (2800 microm in diameter), the perifoveal region 1200-microm-width ring surrounding the central macula), or the overall macular area (5200 microm in diameter), there were no significant differences in the thickness between groups 1 and 2. On an image segmentation analysis, selective thinning of the inner plexiform+ganglion cell layers (P=0.021) was observed only in the perifoveal area of the patients in group 1 compared with that of group 2 by using the mixed-effects model analysis.


CONCLUSIONS
Our study results suggest that chronic exposure to hydroxychloroquine is associated with thinning of the perifoveal inner retinal layers, especially in the ganglion cell and inner plexiform layers, even in the absence of functional or structural clinical changes involving the photoreceptor or retinal pigment epithelial cell layers. This may be a contributing factor as the reason most patients who have early detectable signs of drug toxicity present with paracentral or pericentral scotomas.
Pasadhika
S
S
Department of Ophthalmology and Visual Sciences, Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL 60612, USA.
Fishman
G A
GA
Choi
D
D
Shahidi
M
M
D000328:Adult; D000368:Aged; D000962:Antimalarials / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D008266:Macula Lutea / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012160:Retina / Q000187:drug effects* / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000473:pathology; D012165:Retinal Ganglion Cells / Q000187:drug effects / Q000473:pathology; D041623:Tomography, Optical Coherence / Q000379:methods
D000962:Antimalarials; D018501:Antirheumatic Agents; D006886:Hydroxychloroquine
Lupus. 1996 Jun;5 Suppl 1:S59-64
8803913
Ophthalmology. 2002 Jul;109(7):1377-82
12093666
Ophthalmology. 2002 Mar;109(3):560-8
11874762
Acta Ophthalmol (Copenh). 1990 Apr;68(2):125-30
2356698
Eye (Lond). 2010 Feb;24(2):340-6
19373270
Ophthalmologica. 1965;149:204-8
14315346
Can J Ophthalmol. 1992 Aug;27(5):237-9
1393809
Invest Ophthalmol Vis Sci. 1978 Dec;17(12):1158-75
102610
Am J Ophthalmol. 2008 Nov;146(5):679-87
18707672
Surv Ophthalmol. 1967 Oct;12(5):415-47
4980087
Arch Ophthalmol. 2007 Jun;125(6):775-80
17562988
Curr Opin Ophthalmol. 2004 Apr;15(2):96-101
15021219
Am J Ophthalmol. 1972 Feb;73(2):229-35
4335678
Retina. 2003 Aug;23(4):503-12
12972762
Indian J Ophthalmol. 2008 Nov-Dec;56(6):511-3
18974527
Arthritis Rheum. 1997 Aug;40(8):1482-6
9259429
Doc Ophthalmol. 2008 Mar;116(2):119-27
18080820
Am J Med. 1988 Oct 14;85(4A):18-22
3052053
Ophthalmology. 2003 Jul;110(7):1321-6
12867385